2011
Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis
Holkova B, Tombes M, Shrader E, Cooke S, Wan W, Sankala H, Kmieciak M, Roberts J, Garcia-Manero G, Grant S. Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis. Blood 2011, 118: 2598. DOI: 10.1182/blood.v118.21.2598.2598.Peer-Reviewed Original ResearchRefractory acute leukemiaMyelodysplastic syndromeAcute leukemiaChronic myelogenous leukemiaMyelogenous leukemiaI trialCML-BCBlast crisisDay 1ECOG performance score 0Hematopoietic stem cell transplantationPerformance score 0Phase II dosesRecent preclinical findingsPeripheral sensory neuropathySerious adverse eventsMinute intravenous infusionPhase I trialPhase II evaluationPrimary acute myelogenous leukemiaSchedule of administrationStem cell transplantationBiphenotypic acute leukemiaCombination of bortezomibAcute myelogenous leukemia
1985
Low‐dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia
Roberts JD, Ershler WB, Tindle BH, Stewart JA. Low‐dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia. Cancer 1985, 56: 1001-1005. PMID: 3860278, DOI: 10.1002/1097-0142(19850901)56:5<1001::aid-cncr2820560504>3.0.co;2-p.Peer-Reviewed Original ResearchConceptsLow-dose cytosineAcute myelogenous leukemiaMyelodysplastic syndromeMyelogenous leukemiaTransient hematologic toxicityPeripheral blood countsAppropriate clinical roleTransfusion requirementsHematologic toxicityPartial responseDecreased incidenceBlood countClinical roleLow dosagePatientsSyndromeLeukemiaInfectionIncidenceCessation